Naltrexone Treatment Centers in Alabama

Yes. Providers in Alabama must document a current OUD diagnosis to prescribe naltrexone as part of medication-assisted treatment. The intake assessment typically takes 60–90 minutes and includes a physical exam, drug screen, and psychiatric history — results are used to confirm eligibility.

Vivitrol monthly cost without insurance typically falls between $1,100 and $1,500 per injection in Alabama. The manufacturer Alkermes offers a patient-assistance co-pay savings card; state-funded programs also cover Vivitrol for uninsured patients in many counties.

Yes — Alabama Medicaid can pay retroactively for up to 3 months of prior treatment in most cases, provided you were eligible during that period. Save all receipts and itemized statements from naltrexone providers and submit them to the Medicaid enrollment caseworker.

Yes. Medicare Part B covers methadone through enrolled Opioid Treatment Programs and Part D covers buprenorphine and naltrexone prescriptions. Medicare Advantage plans in Alabama include the same MAT benefits under the integrated plan structure.

Clinics maintain a confidential medical record covering diagnosis, treatment plan, drug screens, counseling notes, and dose history. Records are protected by 42 CFR Part 2 — stricter than HIPAA — and cannot be released without your written consent or a specific court order.

Yes. Buprenorphine and naltrexone prescriptions travel with you. For methadone, your clinic coordinates with an out-of-state guest-dosing OTP; plan at least 2 weeks ahead for domestic travel, longer for international. Ask the clinic about guest-dosing letters.

Yes. Transferring to a different Alabama provider is routine; the new clinic will request records with your consent and continue your current dose. There is no penalty for switching providers — clinical compatibility matters.

Alabama programs generally recommend arranging a ride for the first induction visit, since initial drowsiness is common. After the first 1–2 weeks at a stable dose, patients typically resume driving and most daily activities without restriction.

Buprenorphine and methadone do not test positive on standard 5-panel drug tests — specialty panels are needed. Naltrexone and its metabolites are not screened on standard panels. Share an MAT provider letter with any employer or court drug-testing program to avoid confusion.

Yes. Methadone and buprenorphine are the evidence-based standard of care in pregnancy, endorsed by ACOG and SAMHSA. Staying on MAT protects both mother and fetus; unmedicated withdrawal is riskier than continued MAT. Alabama providers coordinate care with obstetrics.

Yes. Alabama Medicaid covers individual therapy, group sessions, and care coordination at Alabama MAT clinics without separate deductibles in most plans. Peer-recovery support services are also covered in Alabama.

Buprenorphine and naltrexone prescriptions appear on pharmacy records like other prescriptions and are visible to dispensing pharmacies and authorized users of the PDMP. Methadone dispensed at an OTP is not reported to retail pharmacy systems.